[1] 田娜妮,何青青,朱琳,等. 83例药物性肝损伤回顾性分析及保肝药的应用分析[J]. 中国医药导刊,2023,25(2):205-209. [2] 王丹. 药师指导下应用保肝药对预防抗肿瘤药物肝损伤及用药合理性的影响[J]. 当代医学,2022,28(15):142-144. [3] 李钊,黄宛香,莫耀素,等. 护肝药对肺结核并药物性肝损伤的预防及疗效观察[J]. 右江民族医学院学报,2022,44(1):38-42. [4] DORJ G, NAIR N P, BEREZNICKI L, et al.Correction to: Risk factors predictive of adverse drug events and drug-related falls in aged care residents: secondary analysis from the ReMInDAR trial[J]. Drugs & aging, 2023, 40(1):89-89. [5] 曾潇,韦鸿雁,廖金卯,等. 不同类别药物致急性药物性肝损伤的临床特征比较及严重程度影响因素分析[J]. 中国医院药学杂志,2022,42(3):313-317. [6] 张夏兰,沈夕坤,黄玉宇,等. 197例肿瘤患者伴肝功能异常临床保肝用药的合理性分析[J]. 抗感染药学,2021,18(3):321-325. [7] 赖筱姮,吴丽芳,高泉源. 药物性肝损伤患者临床特征及预后情况的回顾性分析[J]. 海峡药学,2022,34(9):113-117. [8] 杨海华,周聪,沈国强,等. 134例替加环素致药物性肝损伤老年患者临床特征回顾性分析[J]. 实用肝脏病杂志,2022,25(3):375-378. [9] DUGBARTEY G J, ALORNYO K K, ADAMS I, et al.Targeting hepatic sulfane sulfur/hydrogen sulfide signaling pathway with α-lipoic acid to prevent diabetes-induced liver injury via upregulating hepatic CSE/3-MST expression[J]. Diabetology & metabolic syndrome, 2022, 14(1):148-149. [10] 王丹. 药师指导下应用保肝药对预防抗肿瘤药物肝损伤及用药合理性的影响[J]. 当代医学,2022,28(15):142-144. [11] 卓海燕,范金海,林云娇,等. 急慢性药物性肝损伤的临床特点及慢性化的因素[J]. 海峡药学,2021,33(12):138-141. [12] SAHU N, RAKSHIT S, NIRALA S K, et al.Naringenin protects hepato-renal tissues against antituberculosis drugs induced toxic manifestations by modulating interleukin-6, insulin like growth factor-1, biochemical and ultra-structural integrity[J]. Molecular biology reports, 2023, 50(2):1019-1031. [13] 冷楠楠,刘永军,邱玉,等. 5种保肝药物治疗药物性肝损伤的网状meta分析[J]. 中国医药科学,2022,12(8):42-47,106. [14] 樊国平,李世鸿,饶福良,等. 三种护肝药物对降低肺结核患者肝损伤的效果比较[J]. 基层医学论坛,2022,26(34):17-19. [15] 洪志明,薛嘉泓,吴静,等. 基于RUCAM量表的ALL患儿化疗药物性肝损伤相关特征分析[J]. 中外医疗,2022,41(13):19-22. |